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Abstract
Background: Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have
become the treatment of choice for post-menopausal women with estrogen receptor positive (ER
+) breast cancer.
However, some patients display de novo or acquired resistance to AI. Interactions between estrogen and growth
factor signaling pathways have been identified in estrogen-responsive cells as one possible reason for acquisition
of resistance. Our laboratory has characterized an autocrine growth factor overexpressed in invasive ductal
carcinoma named PC-Cell Derived Growth Factor (GP88), also known as progranulin. In the present study, we
investigated the role GP88 on the acquisition of resistance to letrozole in ER
+ breast cancer cells
Methods: We used two aromatase overexpressing human breast cancer cell lines MCF-7-CA cells and AC1 cells
and their letrozole resistant counterparts as study models. Effect of stimulating or inhibiting GP88 expression on
proliferation, anchorage-independent growth, survival and letrozole responsiveness was examined.
Results: GP88 induced cell proliferation and conferred letrozole resistance in a time- and dose-dependent fashion.
Conversely, naturally letrozole resistant breast cancer cells displayed a 10-fold increase in GP88 expression when
compared to letrozole sensitive cells. GP88 overexpression, or exogenous addition blocked the inhibitory effect of
letrozole on proliferation, and stimulated survival and soft agar colony formation. In letrozole resistant cells,
silencing GP88 by siRNA inhibited cell proliferation and restored their sensitivity to letrozole.
Conclusion: Our findings provide information on the role of an alternate growth and survival factor on the
acquisition of aromatase inhibitor resistance in ER
+ breast cancer.
Background
Estrogen plays a crucial role in breast and endometrial
carcinomas in addition to being involved in normal phy-
siological processes [1]. The primary site of estrogen
biosynthesis in premenopausal women is the ovaries [2].
After menopause however, peripheral adipose tissue
becomes the main source of estrogen synthesis [2,3].
T h ep r i n c i p a le n z y m er e s p o n s i b l ef o rt h ec o n v e r s i o no f
androgens to estrogens is the cytochrome P450 complex
known as aromatase (CYP 19) [1,2]. Several studies have
demonstrated that this in situ estrogen production plays
a more important role than circulating estrogen in
breast tumor growth [4,5]. Estrogen produces a variety
of cellular responses, such as stimulation of cell prolif-
eration, inhibition of apoptosis, and enhancement of
various peptide growth factor/growth factor receptor
expression in ER
+ breast cancer cells [2,3].
Treatment options for patients with hormone-depen-
dent ER
+ breast cancers are estrogen antagonist such as
tamoxifen, estrogen receptor down regulator such as
Fulvestrant or inhibitors of estrogen biosynthesis such
as aromatase inhibitors [6,7]. Tamoxifen has been the
major agent used to inhibit breast cancer growth until
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receptor (ER) antagonists such as ICI 182,780, also
called Faslodex or Fulvestrant [6]. Aromatase inhibitor
is now the treatment of choice for post-menopausal
breast cancer patients. The inhibitory effect of anti-
estrogen therapy is observed almost exclusively in breast
tumors that are ER
+. However, after prolonged anti-
estrogen therapy, breast carcinoma often progress and
become estrogen-insensitive and refractory to treatment
[8,9]. It is widely documented that the inappropriate
activation of growth factor signaling cascades, either
through overexpression of growth factor, or via up-regu-
lation and increased activation of their target growth
factor receptors or their recruited downstream signaling
elements, can readily promote anti-hormone failure in
breast cancer cells [10-12]. This phenomenon was
demonstrated for the overexpression of multiple growth
factors and their receptors, including heregulins acting
through HER3 and HER4 [13,14], epidermal growth fac-
tor [15] and transforming growth factor (TGF)-a acting
through the epidermal growth factor receptor (EGFR)
[16,17], insulin-like growth factors IGF-I and IGF-II act-
ing through the IGF-IR [18,19], and HER2 receptor con-
tributing to anti-hormone failure either directly when
overexpressed [20-23] or indirectly through heterodi-
merization with other erbB receptor family members
[17].
Increased autocrine or paracrine growth factor signal-
ing network could then bypass the need for ER-
mediated growth stimulation in human breast cancer
cells and would make anti-estrogen therapy ineffective.
Such an elevated or sustained growth factor signaling
within the anti-estrogen-resistant models would even-
tually lead to endocrine insensitivity, or to ER signaling
being circumvented [10-12]. Autocrine and paracrine
growth factor signaling cross-talk with estrogen receptor
(ER) signaling to facilitate tumor growth [24]. Therefore,
increase in autocrine growth factor signaling that med-
iates proliferation signals may induce resistance to endo-
crine therapy [25].
One autocrine growth factor under study in our
laboratory and that has been implicated in the develop-
ment of tamoxifen resistance and estrogen indepen-
dence is PC-cell Derived Growth Factor (GP88) [26].
GP88 also called granulin/epithelin precursor or progra-
nulin, is the largest member of a unique family of
growth modulators characterized by 7.5 cysteine-rich
6KDa polypeptide repeats [27-29]. Published reports
have shown that GP88 was expressed in human breast
cancer cells in a positive correlation with tumorigenesis,
and estradiol (E2) stimulated GP88 expression transcrip-
tionally in ER
+ cells [26]. Inhibition of GP88 expression
by antisense GP88 cDNA transfection in human breast
adenocarcinoma MDA-MB-468 cells led to inhibition of
tumor formation in vitro and in vivo in mouse xenograft
studies [30]. In pathological studies of 203 human breast
cancer biopsies, GP88 was expressed in 80% of invasive
ductal carcinomas in correlation with parameters of
poor prognosis [31] whereas it was negative in benign
lesion and normal mammary epithelial tissues. In addi-
tion, circulating GP88 was found in serum of breast
cancer patients at an increased level when compared to
healthy volunteers [32]. GP88 overexpression in the
human breast cancer cell line, MCF-7, conferred estro-
gen-independent growth, tamoxifen resistance and
increased invasive properties [26,33,34]. Previous studies
also demonstrated that tamoxifen-resistant MCF-7 cells,
selected by culturing cells in the continuous presence of
tamoxifen, expressed higher level of GP88 than tamoxi-
fen-sensitive cells. This suggests that GP88 plays a criti-
cal role in breast cancer tumorigenesis and that there is
a direct relationship between GP88 overexpression and
tamoxifen resistance exists.
Based on the above information, it would be interest-
ing to examine the effect of GP88 on breast cancer cells
response to aromatase inhibitors. Using cellular model
systems established from two independently derived
MCF-7 cell lines overexpressing aromatase activity, we
examined the effect of GP88 on letrozole responsive-
ness. One model consisted of the MCF-7-CA cell line
obtained by transfection of an vector expressing aroma-
tase cDNA [4] and its letrozole resistant counterpart
(LTLT cell line) derived from an MCF-7CA tumor
developed in mice treated with letrozole [23,35]. The
second model included the aromatase overexpressing
breast cancer AC1 cells [36] and letrozole resistant deri-
vative AC1-LetR obtained by continuous cultivation of
AC1 cells in the continuous presence of letrozole.
Methods
The following reagents were obtained: Lipofectamine
and Plus reagent from Life Technologies, Inc. (St. Paul,
MN); agar and zeocin from InVitrogen, (Carlsbad, CA),
androstenedione and b-Estradiol (E2) from Sigma (St.
Louis, MO);, DME/F12 nutrient medium and G418
from Gibco, (La Jolla, CA), fetal bovine serum (FBS)
from Hyclone, (Salt Lake City, Utah); CellTiter-Glo
Reagent from Promega, (Pittsburgh, PA); GP88 SiRNA
and control SiRNAs (smart pool duplex), from Dharma-
con (Chicago, Il). Letrozole was provided to Dr. Angela
Brodie by Novartis. Purified GP88 and all anti-GP88
antibodies and EIA kit to measure GP88 expression
were developed by the Precision Antibody Division of
A&G Pharmaceutical.
Cell lines and culture condition
Human ER
+ breast cancer cells lines MCF-7CA, MCF-
7AC1, LTLT-CA and UMB1-CA cell lines were derived
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cDNA [35,36]. MCF-7AC1 were maintained in DMEM/
F12 medium supplemented with 5% FBS in the presence
of 650 μg/ml G418. LTLT and UMB1 cells [35] were
cultured in steroid-depleted medium consisting of phe-
nol red-free (PRF) DMEM/F12 medium supplemented
with 5% charcoal-stripped (ChX) FBS (PRF-ChX med-
ium) in the presence of 750 μg/ml G418. In addition,
LTLT were cultivated in the presence of 1 μM
Letrozole.
Anchorage-independent growth in Soft Agar
Cells were plated in 6-well plates at 1 × 10
4 cells per well
in 0.33% agarose in PRF-ChX medium layered on top of
0.6% agarose in the same medium with the indicated
treatments. Colony formation was observed after 14-21
days in culture. Following staining with 0.005% crystal
violet, colonies were counted under a microscope.
Cell proliferation assay
C e l l sw e r ep l a t e da t2×1 0
3 cells/well in 96 wells plate
in PRF medium supplemented with 5% ChX FBS (PRF-
ChX medium). The next day, medium was removed and
PRF medium supplemented with the intended treat-
ments and growth factors was added and incubated for
specified times. Cell growth was measured using CellTi-
ter-Glo Reagent following manufacturer’s instructions
(Promega). Recombinant human GP88 produced in
CHO cells was prepared and affinity purified in our
laboratory as described previously [26,33,34].
GP88 cDNA Transfection in MCF-7AC1 cells
Stable transfection of MCF-7AC1 cells with plasmid
DNA of pSectag expression vector containing human
GP88 cDNA [26] was conducted using lipofectamine
and Plus reagent according to manufacturer’sp r o t o c o l .
After transfection, selection of transfected clones was
performed in the presence of 80 μg/ml of selection drug
Zeocin. After two weeks, single clones were picked and
tested for GP88 expression by immunoprecipitation/
western blot as described previously [26] and GP88 pro-
duction in culture medium with GP88 EIA kit developed
in our laboratory.
Aromatase activity assay
Cells were plated at a density of 1.5 × 10
5 cells/well in 6
wells plate in PRF-ChX medium. The next day, cells
were washed with PBS and PRF medium supplemented
with 1% ChX FBS (no G418). Radiolabeled [1 beta
3H]-
androstenedione (23.5 Ci/mmol, Perkin-Elmer) was
added and incubated for the indicated times. Tritium
released from the C-1beta during aromatization to form
3H2O was then measured in the supernatant [34], after
addition of trichloroacetic acid to stop the reaction,
centrifugation, and addition of chloroform. After centri-
fugation, 700 μL of the upper phase was transferred to a
tube to which 700 μL of 2.5% activated charcoal was
added and spun once more. Then 700 μLo ft h es u p e r -
natant was taken and 4 ml scintillation liquid was added
and the radioactivity was measured in a liquid scintilla-
tion counter.
Silencing of GP88 by siRNA in Letrozole resistant cells
LTLT cells or AC1-LetR cells (5,000 cells/well) were
plated in 96 wells plate overnight in ChX-PRF medium.
The next day transfection of GP88 or control SiRNA
(smart pool duplex) (1 μM) was carried out following
the protocol of the manufacturer (DHARMACON). Cell
viability was measured by cell Titer-Glo assay and the
level of GP88 was measured both by western blot analy-
sis and EIA as indicated below.
Measurement of GP88 expression by Western Blot
analysis and by EIA
GP88 expression in breast cancer cells and culture
media was measured using two methods: Western blot
analysis and EIA. For western blot analysis of GP88
expression in cell lysates, cells treated with GP88 or
control siRNA (1 μM) were washed with ice cold PBS
twice and lysed with RIPA buffer containing protease
inhibitors (150 mM NaCl, 50 mM Tris-HCL, 1% NP-40,
0.25% Na-Deoxycholate, 1 mM EDTA, 1 μg/ml Aproti-
nin, Leupeptin, and Pepstatin, 1 mM Na3VO4, 1 mM
PMSF and 1 mM NaF. 50 μg of total protein lysate were
analyzed by 10% SDS gel electrophoresis. Western blot
analysis was performed as described previously [26]. For
Western blot analysis of GP88 in culture medium, con-
ditioned medium normalized to cell number was col-
lected and brought up to 1 ml volume and incubated
with 1 μg of anti-human GP88 rabbit polyclonal anti-
body in the presence of 30 μl of protein G agarose over-
night at 4°C. The next day, the agarose beads were spun
and washed three times with ice cold PBS and resus-
pended in 40 μL of 2x sample buffer to perform SDS-
PAGE on a 7.5% polyacrylamide gel followed by western
blot analysis using anti-human GP88 mouse monoclonal
antibody also developed in our laboratory [26]. Quantifi-
cation of GP88 in culture medium was also carried out
using an GP88 EIA kit developed in our laboratory.
Determination of Bcl-2 expression in response to GP88
and letrozole
The ability of letrozole to down regulate bcl-2 expression
was examined for MCF-7-AC1 cells. AC1 cells were pla-
t e da t1 . 5×1 0
5 cells in 35 mm plate and incubated in
PRF medium with 5% ChX-FBS (ChX-PRF). The next
day, the medium was removed and fresh medium was
added with the treatments: 25 nM of androstenedione
Abrhale et al. BMC Cancer 2011, 11:231
http://www.biomedcentral.com/1471-2407/11/231
Page 3 of 10(AD) or AD with 5 nM letrozole (Let) in the absence or
presence of GP88 at the indicated concentrations. Con-
trol corresponded to cells cultivated in ChX-PRF. 48
hours later, total RNA was extracted using Trizol™
reagent (InVitrogen) and resuspended in DEPC-treated
water for measuring bcl-2 and GAPDH mRNA expres-
sion by RT-PCR. PCR conditions and the oligonucleotide
sequences of the specific forward and reverse primers for
bcl-2 and GAPDH have been described previously [33].
Statistical Analysis
All experiments were performed in triplicates and
repeated at least three times. Data are expressed as
mean with standard deviation. Student’s t-test was used
to determine the significance of results with p < 0.05 as
statistically significant.
Results
GP88 induces cell proliferation and confers letrozole
resistance in vitro
We examined the effect of human GP88 on proliferation
and letrozole responsiveness of MCF-7 AC1 human breast
cancer cells overexpressing aromatase. As shown in figure
1, GP88 added at concentrations from 150 ng/ml to 600
ng/ml stimulated the proliferation of MCF-7AC1 cells,
maintained in steroid-depleted conditions in a dose-
dependent fashion. Stimulation of proliferation by GP88
reached a plateau at 300 ng/ml with a 2-fold increase over
control, (p < 0.01) compared to 2.6-fold observed with
25 nM androstenedione (AD) (p < 0.01), the substrate
that is converted into estrogen by aromatase enzymatic
activity (figure 1). Letrozole treatment of AC1 cells in the
presence of AD resulted in a dose-dependent inhibition
of growth (figure 2). Addition of 50 nM and 100 nM of
letrozole inhibited proliferation by 66% and 76% respec-
tively. Addition of GP88 blocked the inhibitory effect of
letrozole (figure 2). In the presence of GP88, 50 nM
letrozole had no inhibitory effect on AC1 cells, whereas
the inhibitory effect of 100 nM letrozole was reduced
from 76% to 22% (p < 0.01).
GP88 stimulate anchorage-independent growth in
aromatase overexpressing AC1 cells
Anchorage-independent growth is a hallmark of cancer
cell transformation. The ability of exogenously added
GP88 to stimulate anchorage-independent growth and
confer MCF-7AC1 cells resistance to letrozole was
investigated. As described in the method section, cells
plated at 1 × 10
4 in soft agar in steroid-depleted med-
ium were treated with AD, GP88 or E2 in the absence
of letrozole. As shown in figure 3A, addition of GP88
resulted in a 20-fold increase in the number of colonies
forming in soft agar (p < 0.01), similarly to what was
observed for androstenedione (AD) and for Estradiol,
known growth stimulators of aromatase overexpressing
breast cancer cells. As shown in figure 3B, addition of
letrozole (200 nM) to cells cultivated in the presence of
AD resulted in a 53% inhibition of colony growth in soft
agar. In addition to stimulating colony growth, GP88
(300 ng/ml) reversed the inhibitory effect of letrozole
similarly to E2 taken as control (figure 3A).
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Figure 1 GP88 induces AC1 cell proliferation in vitro.5×1 0
4
cells/plate (35 mm well plates) MCF-7AC1 cells were plated in PRF
medium supplemented with 5% Charcoal treated FBS overnight.
The next day, medium was removed and serum free medium was
added without or with increasing concentration of GP88: 150 ng/ml
(P-150), 300 ng/ml (P-300) and 600 ng/ml (P-600) or 25 nM
androstenedione (AD). After 6 days, cells were trypsinized and cell
number was determined by counting cells with a hemocytometer.
Experiment was performed three times in triplicate.
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Figure 2 GP88 confers AC1 cells Letrozole resistance in vitro.
2000 cells/well (96 well plates) MCF-7AC1 cells were plated in PRF
medium supplemented with 5% ChX FBS overnight The next day,
medium was removed and serum free medium was added with
and without 300 ng/ml GP88 (GP88 (P)), 25 nM androstenedione
(AD) and letrozole (L) 50 nM and 100 nM, 200 nM. Cell proliferation
was measured after 6 days using Cell Titer-Glo assay. Experiment
was performed in triplicates with p < 0.01.
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transfectants
Our data so far show that exogenously-added GP88
induces cell proliferation and anchorage- independent
growth in the presence or absence of letrozole. Next, we
examined the ability of AC1 cells stably transfected with
cDNA coding for human GP88 (AC1-P) to grow in ancho-
rage-independent conditions with or without increasing
doses of letrozole. Similarly to the results obtained with
exogenously added GP88, AC1-P cells plated in soft agar
yielded an increased number of colonies in PRF-ChX med-
ium when compared to AC1-EV cells that did not overex-
press GP88. Moreover, addition of letrozole did not
decrease colony formation in AC1-P cells in contrast to its
inhibitory effect observed with transfected empty vector
AC1 cells used as controls (figure 4A). Interestingly, there
were no differences in response to AD between the AC1-
EV and AC1-P cell lines indicating that even though the
cells overexpressing GP88 could proliferate in steroid-free
medium, they remained responsive to AD (figure 4A).
Similarly to what was observed with AC1 cells, overex-
pression of GP88 in another aromatase overexpressing cell
lines MCF-7CA cells also resulted in a stimulation of
growth in soft agar in steroid-depleted medium in the
absence of AD (figure 4B).
GP88 does not affect aromatase enzymatic activity
The ability of GP88 overexpressing AC1 cells to respond
to androstenedione suggests that the activity of aroma-
tase was not affected by GP88. However, to verify that
GP88 overexpression had no effect on aromatase, aro-
matase enzymatic activity was measured in the AC1,
and AC1-P cells as described in the method section.
There were no differences in aromatase activity between
the cells AC1 and AC1-P cells (figure 4C). This indi-
cates that expression of GP88 has no effect on aroma-
tase enzyme activity in AC1-P cells.
GP88 blocks bcl-2 down regulation induced by letrozole
Bcl-2 is a key apoptosis regulator that is down regu-
lated in many cell types in response to treatment lead-
ing to activation of apoptosis [37]. Bcl-2 expression
was examined in AC1 and AC1-P cells treated with
androstenedione with and without letrozole. As
expected, AD stimulated bcl-2 expression. Addition of
letrozole induced the down-regulation of bcl-2 protein
expression in AC1 cells (figure 5A). Addition of GP88
prevented bcl-2 down regulation in a dose-dependent
manner when compared to cells treated with AD and
letrozole (figure 5A). Figure 5B, provides a quantifica-
tion of the results from triplicate experiments and
shows that letrozole inhibited bcl-2 mRNA expression
by 61%, whereas inhibition of bcl-2 expression by
letrozole was only 24% in the presence of 300 ng/ml
GP88 (p < 0.05).
Letrozole resistant breast cancer cells overexpress GP88
We then examined GP88 expression in cells made natu-
rally resistant to letrozole. Two cell lines were used. The
first one termed Long Term Letrozole Treated tumor
cells (LTLT) derives from a tumor developed by MCF-
7CA cells injected into nude mice following long term
exposure to letrozole [23]. The LTLT cells can prolifer-
ate in the continuous presence of 1 μMl e t r o z o l e[ 3 8 ] .
The second cell line was AC1-LetR cells derived from
AC1 cells that were rendered resistant to Letrozole by
cultivating AC1 cells for prolonged periods of time in
the continuous presence of 5 nM letrozole.
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Figure 3 GP88 induces anchorage independent colony
formation and confers letrozole resistance comparable to E2.
A: AC1 cells (1 × 10
4 cells/well in 6-well plate) were plated in soft
agar plates as described in the Method section in (A) PRF-ChX with
and without 300 ng/ml GP88 (P), 25 nM androstenedione (AD) and
200 nM letrozole (L) for 2 weeks. (B) in DMEM/F12 supplemented
with 5%FBS, E2 = 10
-8 M, 25 nM AD, +/- 300 ng/ml GP88 cultured
for 3weeks. Fresh medium was added every 3 to 4 days. At the end
of the experiment, colonies were fixed with crystal violet and
counted, p < 0.01
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when compared to the letrozole sensitive parent cell line
MCF-7 CA (figure 6A). GP88 level secreted by the cells
was also measured by GP88 EIA developed in our
laboratory. LTLT cells had a 13.7-fold increase in the
level of GP88 secreted when compared to the letrozole
sensitive parent cell line MCF-7CA. The level was 0.8 ±
0.07 ng/10
6 cells in MCF-7CA and 11 ± 2 ng/10
6 cells
in LTLT cells, respectively.
Silencing GP88 by siRNA reduces cell viability and
restores sensitivity to letrozole
The above result shows that GP88 overexpression
in LTLT cells is associated with letrozole resistance.
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Figure 4 Overexpression of GP88 in AC1 cells and MCF-7CA
cells confer letrozole resistance. A: GP88 overexpressing AC1 cells
(AC1-P) cells were developed by stable transfection of GP88 cDNA
expression vector as described in the method section. As control,
AC1-EV cells were developed by transfecting empty vector (AC1-EV).
For measuring anchorage-independent growth of stably transfected
AC1-P cells, AC1-P cells were plated at a density of 5 × 10
3 cells/
well in a 12 wells plate and cultivated for 2 weeks with/without 200
nM letrozole, 25 nM AD, 300 ng/ml GP88 for the AC1 and CA1-EV
in 5% ChX-FBS supplemented medium containing soft agar.
Medium was changed every 3-4 days.B: Stimulation of anchorage
independent growth of MCF-7-CA cells overexpressing GP88. The
aromatase-overexpressing cells MCF-7CA were transfected with
expression vector containing GP88 cDNA (CA-P) or with empty
vector (CA-EV). Anchorage independent growth of stable
transfectants was examined as described above.C: Comparison of
aromatase enzymatic activity in AC1 and AC1-P cells. AC1 and AC1-
P cells were plated in 6-well plates at a density of 1.5 × 10
5 cells/
well. Measurement of aromatase activity assay was performed
following the protocol described in the method section.
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Figure 5 Bcl-2 upregulation by GP88 in AC1 cells.A :T h ea b i l i t y
of letrozole to down regulate bcl-2 expression was examined for
AC1. AC1 cells were plated at 1.5 × 10
5 cells/well in 6-well plate
and incubated in PRF medium with 5% ChX-FBS. The next day, the
medium was removed and fresh PRF-5%ChX-FBS medium was
added with the indicated treatments 25 nM androstenedione (AD)
or AD with 200 nM letrozole (ADL) alone or in the presence of
GP88 (150 ng/ml and 300 ng/ml). After 48 hours, total RNA was
extracted with Trizol™. Bcl-2 mRNA expression was determined by
RT-PCR and examined by agarose gel electrophoresis and staining
by ethidium bromide as described in the method section. GAPDH
mRNA expression was examined as internal control for equal
loading. B: Bcl-2 and GAPDH band intensities of triplicate
experiments were determined by densitometry scanning using a
UVP gel densitometer. Relative average intensity of bcl-2 bands
from the triplicate experiments in each experimental group were
then normalized using GAPDH as an internal standard and
expressed as bars ± SD, p < 0.05.
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Figure 6 Effect of silencing GP88 expression on cell proliferation and letrozole responsiveness. A: Top panel: Comparison of GP88
expression in MCF-7CA cells (letrozole sensitive) and LTLT cells (letrozole resistant cells). Bottom panel: LTLT-CA cells were treated with either siRNA
control or with GP88 siRNA for 48 hours before harvesting the cells to determine GP88 expression. GP88 level was determined by IP-Western
analysis and normalized to cell number as described previously (Lu and Serrero, 2001). (B) LTLT-CA cells were transfected with GP88 siRNA or
control siRNA according to manufacturer’s instructions one day before being plated at 2 × 10
3 cells/well in 96 well plates in PRF-5%ChX medium
and incubated for the time indicated. Cell proliferation was then measured by using the cellTiter-Glo
R assay using a luminometer (Molecular
Devices).(C) LTLT-CA cells were transfected with either GP88 siRNA or Control siRNA as described above. The next day, cells were plated at 2 × 10
3
cells/well in 96-well plate and incubated in PRF-ChX medium for 24 hrs more. After 24 hrs, the medium was removed and cells were washed with
PRF medium twice. Cells were then incubated in serum free fresh medium with the indicated concentration of letrozole for 3 days. After 3 days
cells were counted using cellTiter-Glo assay, p < 0.05. D) Increase of GP88 expression in AC1-LetR cells derived from AC1 cells rendered letrozole
resistant by long term culture in the presence of 5 nM letrozole. E) Effect of silencing GP88 on proliferation of AC1-LetR cells. AC1-LetR cells were
transfected with either control siRNA or GP88 siRNA as described in the method section. Proliferation was measured after 24 and 48 hours
exposure by cellTiter-Glo
R assay, p < 0.05.
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sion and proliferation and letrozole responsiveness of
LTLT cells. To answer this question LTLT cells were
transfected with SiRNA for GP88 and control SiRNA
(1 μM). The level of GP88 in transfected cells was tested
both by EIA and western blot analysis. Data from figure
6 A( b o t t o mp a n e l )s h o w e dt h a tG P 8 8e x p r e s s i o nw a s
significantly down regulated within 24 hrs after GP88
SiRNA transfection. LTLT cell proliferation was inhib-
ited by transfection with GP88 SiRNA when compared
to cells transfected with non specific control SiRNA
(figure 6B). Moreover, GP88 SiRNA treatment of LTLT
cells resulted in a 50% growth inhibition upon addition
of various doses of 1-3 μM letrozole in contrast to the
cells transfected with control SiRNA that showed no
response to letrozole (figure 6C). These data show that
inhibition of GP88 expression significantly restored
letrozole sensitivity of LTLT cells.
We then examined whether GP88 overexpression was
also found in other breast cancer cell lines that are
resistant to letrozole. As mentioned above, we developed
a letrozole resistant cell line named AC1-LetR by con-
tinuous cultivation of AC1 cells in the presence of 5 nM
letrozole. We also show here that the AC1-LetR cells
overexpress GP88 (figure 6D). This overexpression was
also quantified by GP88 EIA. The results indicate that
GP88 expression was 30-fold higher in AC1-LetR cells
(23 ± 2 ng/10
6 cells) than in the letrozole sensitive AC1
cells (0.7 ± 0.2 ng/10
6 cells). Silencing of GP88 by
SiRNA in AC1Let-R cells prevented the cell from prolif-
erating when compared to AC1-LetR cells transfected
with control siRNA (figure 6E), similarly to what was
observed with the LTLT cells (figure 6A-C).
Discussion
Development of drug resistance is a recurring problem
in treating ER
+ breast cancer patients even with the
recently introduced aromatase inhibitors [8-9; 36-40].
Overexpression of several growth factors and growth
factor receptors overexpression and cross talk with ER
have been described as some of the major changes as
associated or causing such resistance [17,22,39]. We
show here that an alternate growth/survival factor GP88
(progranulin), previously identified as playing a role in
breast cancer tumorigenesis [28,29], is involved in con-
ferring letrozole resistance using two aromatase overex-
pressing breast cancer cells as study models. The
present study demonstrates that exogenously added
GP88 induces AC1 and MCF-7CA growth in steroid-
depleted medium in both anchorage-dependent and
independent conditions. In addition, Letrozole induced
down regulation of bcl-2 expression whereas GP88 pre-
vented such down regulatio n .W eh a v ea l s om e a s u r e d
viability of the cells treated with androstenedione only
(AD), with AD and letrozole (ADL) and with AD, letro-
zole and GP88 (ADLP). Letrozole reduced AC1 cell via-
bility by 50% whereas addition of GP88 to letrozole
treated cells restored viability to the level found on AD
treated cells (data not shown).
Interestingly, GP88 cells treated with GP88 or stably
overexpressing GP88 formed larger and more numerous
colonies in soft agar in steroid-depleted medium even in
the absence of androstenedione, the substrate that is
converted to estrogen by aromatase. In fact, GP88 had
similar growth stimulatory activity as androstenedione
or estradiol. Moreover, it was demonstrated that two
letrozole resistant cell lines, AC1-LetR and LTLT-CA
cells, overexpressed GP88 by 30-fold when compared to
letrozole sensitive cells, thereby strongly suggesting a
direct relationship between GP88 overexpression and
development of resistance to letrozole.
Blocking GP88 expression by SiRNA transfection
results in inhibition of cell proliferation in cell lines,
AC1-LetR and LTLT-CA cells. We also demonstrate
that SiRNA treatment partially restores LTLT-CA cells
sensitivity to letrozole. These data provide additional
support to our previous findings that GP88 could substi-
tute for estradiol to stimulate proliferation, in steroid-
depleted medium and confer tamoxifen resistance to
MCF-7 cells both in vitro and in vivo [32]. Our previous
pathological study with paraffin-embedded breast cancer
biopsies has shown that GP88 is expressed in ER
+ inva-
sive ductal carcinoma (IDC) in association with poor
prognosis whereas GP88 expression was negative in
benign lesions and normal mammary epithelial tissues
[31] supporting the fact that GP88 could play a role in
clinical outcomes of breast cancer patients. Moreover,
we showed by a retrospective clinical study that high
GP88 expression measured by IHC in tumor biopsies of
patients with ER
+ IDC was associated with a significant
decrease in disease-free and overall survivals (Serrero et
al, submitted to publication). In addition, a recent pub-
lished study has shown that GP88 also plays a role in
triple negative breast cancer (ER, PR and Her2 negative)
with high GP88 expression associated with poor survival
outcome [41].
Overexpression of growth factors and, growth factor
receptors will make aromatase overexpressing cells able
to by-pass the need of estradiol for proliferation. Several
mechanisms have been hypothesized, in particular cross-
talking with ERa and/or constitutive activation of
MAPK leading to the down regulation of ERa,m a k i n g
the tumors insensitive to estradiol and thus to AIs
therapies [23,40]. Such possibilities have been described
for the letrozole resistant cell line LTLT cells that have
been isolated from tumor treated with letrozole for a
prolonged period of time [23]. These cells were found
to have lower level of ERa and higher Her-2 level than
Abrhale et al. BMC Cancer 2011, 11:231
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The cells appear to survive estrogen deprivation by the
activation of Her-2/MAPK pathway [42]. In fact, for
these letrozole resistant cells, the combination of letro-
zole and trastuzumab resulted in superior outcome in
inhibiting tumor growth in vivo over letrozole or trastu-
zumab alone leading to inhibition of tumor growth, in
contrast to MCF-7CA cells where letrozole alone was as
effective as trastuzumab in combination with letrozole.
This indicates that overexpression of Her-2 is a major
contributor of letrozole resistance of LTLT cells. We
show here that the autocrine growth factor GP88 con-
fers letrozole resistance to MCF-CA cells and that in
LTLT cells that overexpress GP88, inhibition of GP88
expression by SiRNA partially restores letrozole respon-
siveness. In addition, GP88 also conferred letrozole
resistance to AC1 cell line, another aromatase overex-
pressing cell line. Concerning the possible mechanisms
by which GP88 confers letrozole resistance, we show
here that AC1 cells overexpressing GP88 can still be sti-
mulated by androstenedione (figure 4A) in steroid-
depleted medium and by estradiol ( data not shown)
indicating that the letrozole resistance caused by GP88
is not due to the cells becoming estrogen independent
or not expressing estrogen receptors. Moreover, as
shown in figure 4C, aromatase enzymatic activity was
not affected by GP88 overexpression thereby suggesting
that GP88 expression did not result in a defect in aro-
matase expression or function. The fact that GP88 has
been shown to be a potent proliferation and anti-apop-
totic factor for breast cancer cells [26,33,34] would sug-
gest that GP88 confers resistance to the killing effect of
letrozole by providing growth and survival advantage to
the cells rather than by blocking estrogen response or
by inhibiting aromatase activity.
It is also interesting to note that we have shown pre-
viously that GP88 activates Her-2 phosphorylation in
breast cancer cells through the ERK1/2 and Akt path-
ways [43]. This would suggest the association of GP88
and Her-2 in conferring resistance to letrozole. How-
ever, our pathological studies with breast cancer tumor
biopsies have indicated that GP88 and Her-2 were inde-
pendent biomarkers [31], suggesting that not all of
GP88 effects on letrozole resistance are necessarily
mediated via GP88’s ability to cross-talk with Her-2.
Conclusions
Understanding the role and mechanisms of GP88 in the
development of resistance to anti-hormonal treatments
could contribute to improving the treatment of breast
cancer. Based on our pathological studies, it would be
interesting to examine if overexpression of GP88 in
tumor tissue s is associated with poor response to AI.
Moreover, combination of drugs that include the
inhibition of growth factors and anti-hormones could
provide new avenues to treat breast cancer patients and
overcome resistance. Our findings provide a novel para-
digm for the acquisition of aromatase inhibitor resistant
breast cancer and could suggest new therapeutic
approaches.
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